The US FDA has sent Galderma a Complete Response Letter (CRL — a formal communication stating that a biologics license application cannot be approved in its current form) for relabotulinumtoxinA, the company's investigational next-generation botulinum toxin. The agency delivered the letter to the Swiss dermatology-focused pharmaceutical company, according to a report by The Dermatology Digest.

The CRL concerns relabotulinumtoxinA, Galderma's candidate successor in the botulinum toxin space. Galderma already markets the portfolio it built around injectable aesthetics and therapeutic neurotoxins. A CRL does not constitute a final rejection; it identifies deficiencies the sponsor must resolve before the agency will reconsider approval.

What does the letter actually change?

In practical terms, a Complete Response Letter pauses the approval pathway. The FDA issues a CRL when it judges an application deficient on manufacturing, clinical data, labeling or facility inspection grounds. The letter itself specifies the deficiencies, though the report available at publication does not detail which of these categories applies here.

What the public record does not yet say matters as much as what it does. The report does not state which indication the CRL affects, whether the FDA requested additional clinical trials, or whether the deficiencies relate to manufacturing or facility inspection rather than efficacy data. Galderma has not, in the available reporting, disclosed a timeline for resubmission.

Why the asset matters to Galderma

Botulinum toxins anchor the aesthetics market. Galderma competes in a field where next-generation molecules promise faster onset, longer duration or improved purity relative to established products. Any delay in relabotulinumtoxinA therefore carries commercial weight: competitors continue to advance their own pipeline candidates while the application remains unresolved.

A next-generation toxin is typically positioned as a differentiated follow-on rather than a me-too product. Whether relabotulinumtoxinA can substantiate that positioning now depends on how quickly Galderma addresses the FDA's concerns. That burden of proof sits with the sponsor, not the regulator.

What comes next?

Companies receiving a CRL generally respond by submitting amended data, negotiating labeling changes, or correcting manufacturing deficiencies, then resuming review. Investors and clinicians will look for Galderma's formal response, which should clarify the letter's substance and a resubmission timeline. Until the company discloses those details, the clinical and commercial implications for relabotulinumtoxinA remain, by necessity, an open question.

Reported by The Dermatology Digest; Galderma had not published full CRL details at the time of writing.